| SIM0613 in Participants With Advanced Solid Tumors (NCT07618260) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2026-05-15 |
| A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors (NCT07749703) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2026-03-31 |
| First in Human Study of SIM0610 in Solid Tumors (NCT07348211) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2026-01-19 |
| A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult Participants (NCT07345364) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2026-01-12 |
| An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants (NCT07357610) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2026-01-05 |
| A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer (NCT07361003) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2025-11-12 |
| A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors (NCT07265921) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2025-11-07 |
| A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis (NCT07175233) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2025-10-27 |
| A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors (NCT07050459) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2025-05-20 |
| A Phase I Study of SIM0388 in Participants With Malignant Ascites. (NCT07007988) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2025-04-24 |
| Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors (NCT06686745) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2024-12-06 |
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) (NCT06680921) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2024-11-14 |
| Mass Balance Clinical Trial of SIM0270 (NCT06654791) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2024-10-17 |
| Evaluate the Effects of Food on the Pharmacokinetics of SIM0270 (NCT06536036) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2024-07-23 |
| Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma (NCT06375044) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2024-05-24 |
| Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors (NCT06331559) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2024-03-19 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC (NCT06186414) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2024-01-23 |
| Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects (NCT06326723) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2023-09-04 |
| A Study of Daridorexant in Chinese Patients With Insomnia Disorder (NCT06010693) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2023-08-28 |
| Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects (NCT05826249) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2023-04-07 |
| Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors (NCT05718219) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2023-03-29 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors (NCT05781360) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2023-03-08 |
| Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir (NCT05731804) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2023-03-01 |
| Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants (NCT05665647) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-12-29 |
| A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma (NCT05569057) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-09-30 |
| A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 (NCT05506176) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-08-19 |
| Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants (NCT05475834) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-07-21 |
| To Evaluate SSD8432/Ritonavir in Adults With COVID-19 (NCT05373433) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-05-26 |
| Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study (NCT05373446) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-05-20 |
| Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer (NCT05293964) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-05-18 |
| A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors (NCT05528055) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-05-18 |
| To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 (NCT05369676) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-05-12 |
| A Phase I Clinical Study of SSD8432 in Healthy Adult Subjects (NCT05339646) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-04-07 |
| A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors (NCT05254665) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-02-01 |
| A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors (NCT05148195) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-12-22 |
| The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers (NCT05200728) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-12-06 |
| PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy (NCT04942301) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-07-30 |
| A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions (NCT04914598) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-07-28 |
| A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer (NCT04908787) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-06-11 |
| Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients (NCT04902885) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-05-25 |
| A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. (NCT04830644) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-03-22 |
| An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations. (NCT04671849) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2020-12-21 |
| A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors (NCT04413227) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2020-04-02 |
| A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. (NCT03763123) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2018-04-24 |
| A Pilot Bioequivalence Study of Pomalidomide (NCT03424928) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2018-01-19 |